Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Gene test proposed following neonatal encephalopathy
Wed August 5th - Gene profiling could predict outcomes for new born babies following oxygen deprivation, as well as help explain the mechanisms causing the damage, British researchers say. More
COVID-19 infection possible in early gestation
Wed August 5th - Genes which allow COVID-19 infection to take hold are present in the first trimester of pregnancy, researchers report today. More
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...

World's first 'Darwinian' cancer drug programme announced

Thursday May 16th, 2019

The world’s first ‘Darwinian’ drug discovery programme, designed to tackle cancer’s ability to evolve resistance to treatment, is to be launched in the UK, it is announced today.

The Institute of Cancer Research (ICR), London, has committed an initial £75 million in creating a global centre of expertise in anti-evolution therapies, which could help to improve cure rates. It is seeking a further £15 million to complete the new building and equip it.

ICR scientists hope to use evolutionary science to ‘herd’ cancers with anti-evolution drugs and combinations to deliver long-term control and effective cures.

They say this should replace the traditional use of chemotherapy, which has failed too often because it helps to fuel ‘survival of the nastiest’ competition and evolution among cancer cells.

The new Centre for Cancer Drug Discovery will bring together researchers from different disciplines across drug discovery and evolutionary science under one roof and will lead on pioneering projects such as using artificial intelligence (AI) and advanced maths to ‘herd’ cancer so it is forced to adapt to one treatment by developing weaknesses against others

Other projects will include the creation of the world’s first anti-evolution cancer drug and the development of multi-drug combinations that block several different cancer genes at once or that boost the immune system.

Professor Paul Workman, chief executive of The Institute of Cancer Research, London, said: “Cancer’s ability to adapt, evolve and become drug resistant is the cause of the vast majority of deaths from the disease and the biggest challenge we face in overcoming it.

“We firmly believe that, with further research, we can find ways to make cancer a manageable disease in the long term and one that is more often curable, so patients can live longer and with a better quality of life. But that research will need support and our new Centre will dramatically accelerate the progress we’re already making.”

Dr Andrea Sottoriva, who will be deputy director of cancer evolution in the new Centre for Cancer Drug Discovery, said: “Artificial intelligence and mathematical predictive methods have huge potential to get inside cancer’s head and predict what it is going to do next and how it will respond to new treatments.

“Within our new Centre for Cancer Drug Discovery, we plan to use cancer’s survival instinct against it through an approach we call ‘evolutionary herding’. By encouraging cancer to evolve resistance to a treatment of our choice, we can cause it to develop weaknesses against other drugs – and hopefully send it down dead ends and to its own destruction.”

Tags: Cancer | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)